KRMD

Analyst Ratings on REPRO-MED Systems: Chase Knickerbocker from Craig-Hallum maintains a Buy rating on REPRO-MED Systems (KRMD), while Canaccord Genuity also issued a Buy, and Piper Sandler reiterated a Hold rating.

Stock Performance Overview: REPRO-MED Systems has fluctuated between a one-year high of $5.05 and a low of $2.04, with an average trading volume of 187.9K shares.

Financial Performance: KORU Medical Systems reported a 23% increase in fourth quarter net revenues to $8.8 million and an 18% increase for the full year 2024, totaling $33.6 million, with improvements in gross margins and a reduction in net loss.

2025 Guidance and Business Updates: The company anticipates net revenues of $38.0 - $39.0 million for 2025, alongside operational cash flow positivity, and plans to rename its Novel Therapies business to "Pharma Services and Clinical Trials" to better reflect its focus on collaborations prior to drug clearance.

Analyst Downgrades: Several Wall Street analysts downgraded their ratings for Informatica Inc and KORU Medical Systems, with Informatica's price target reduced significantly from $35 to $19 by Baird and from $34 to $19 by Wells Fargo.

Other Downgrades: Floor & Decor Holdings also faced a downgrade from Outperform to Neutral, with its price target lowered from $110 to $100 by Wedbush analyst Seth Basham.

Analyst Downgrade: Piper Sandler analyst Jason Bednar downgraded Koru Medical (KRMD) to Neutral from Overweight, citing the stock's high valuation despite improved execution and potential revenue growth.

Concerns Raised: The firm expressed unease about tougher comparisons in the U.S. subcutaneous immunoglobulin market, limited gross margin upside for 2025 and 2026, and delayed revenue catalysts, suggesting better risk/reward opportunities elsewhere.

Analyst Ratings: Craig-Hallum analyst Chase Knickerbocker has maintained a Buy rating on REPRO-MED Systems (KRMD), which closed at $4.85, while Lake Street also issued a Buy rating with a $5.00 price target.

Market Consensus: The overall analyst consensus for REPRO-MED Systems is a Strong Buy, with an average price target of $4.50 indicating a potential downside of 7.22%, and Knickerbocker is recognized as a 5-star analyst with a notable success rate.

Analyst Rating and Price Target: Frank Takkinen from Lake Street has maintained a Buy rating on REPRO-MED Systems (KRMD) with a price target of $5.00, while the current analyst consensus is a Strong Buy with an average price target of $4.50.

Company Performance: REPRO-MED Systems reported quarterly revenue of $8.18 million and a GAAP net loss of $1.58 million for the quarter ending September 30, showing an increase in revenue compared to the previous year but a larger net loss.

KORU Medical's New Collaboration: KORU Medical Systems has signed an agreement with a global pharmaceutical company to develop a next-generation subcutaneous immunoglobulin therapy infusion system, collaborating closely with SCHOTT Pharma to enhance patient convenience and integration with drug delivery methods.

Focus on Patient-Centric Solutions: The new infusion system aims to facilitate easier home therapy for patients using both vials and prefilled syringes, aligning with KORU Medical's mission to improve the quality of life for patients through innovative medical technology.

Collaboration Announcement: KORU Medical Systems has partnered with a global pharmaceutical manufacturer to conduct a Phase III clinical trial for an expanded indication of a drug therapy aimed at treating a rare renal disorder, potentially benefiting around 30,000 patients.

Market Growth and Product Overview: The company continues to see growth in the large volume subcutaneous market, with over 2 million infusions administered annually through its Freedom Infusion System, which includes various innovative products designed for patient self-administration and clinical use.

Financial Performance: KORU Medical Systems reported preliminary unaudited net revenues of $8.9 million for Q4 2024, a 23% increase year-over-year, and full-year revenues of $33.7 million, up 18% from the previous year, with an ending cash balance of $9.6 million.

Strategic Growth: The company’s CEO highlighted successful execution of their strategic plan, including market share expansion in the US and international growth, while also improving margins and cash flow management, setting a positive outlook for 2025.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

KORU Medical Conference Participation: KORU Medical Systems will present at Piper Sandler’s 36th Annual Healthcare Conference on December 5, 2024, at 11:00 am ET, with a live and archived webcast available on their website.

Company Overview: KORU Medical specializes in innovative large volume subcutaneous infusion solutions, including the FREEDOM Syringe Infusion System, which enhances patient quality of life and supports biopharmaceutical companies during drug development.

Financial Performance: KORU Medical Systems reported a 17% increase in third-quarter net revenues to $8.2 million, with notable growth in novel therapies at 276%, and raised its full-year revenue guidance to between $32.75 - $33.25 million.

Operational Highlights: The company achieved a gross profit of $5.2 million, improved its gross margin to 63%, and demonstrated strong nursing preference for its FreedomEdge® system during the PODD Conference, indicating positive reception of its products in the market.

Upcoming Financial Results Announcement: KORU Medical Systems will report its third quarter 2024 financial results on November 13, 2024, followed by a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates.

Company Overview: KORU Medical specializes in developing patient-centric large volume subcutaneous infusion solutions, including the FREEDOM Syringe Infusion System, which is designed for self-administration and use in ambulatory infusion centers.

Company Participation: KORU Medical Systems will participate in investor meetings at the 8th Annual Lake Street Best Ideas Growth Conference in New York on September 12, 2024.

Product Overview: KORU Medical specializes in large volume subcutaneous infusion solutions, including the FREEDOM Syringe Infusion System, which enhances patient self-administration and is utilized in clinical trials.

KORU Medical Systems Inc. Earnings Report: The company reported a quarterly loss of $0.02 per share, outperforming the Zacks Consensus Estimate of a loss of $0.04, with revenues of $8.43 million exceeding expectations by 12.04%. Despite this, KORU's shares have declined about 8.8% since the start of the year.

Future Outlook and Industry Context: The earnings outlook for KORU is currently unfavorable, reflected in a Zacks Rank #4 (Sell), indicating expected underperformance in the near future. Additionally, the Medical - Instruments industry ranks in the bottom 42% of Zacks industries, which may impact stock performance.

KORU Medical Systems Inc. Financial Performance:

• Reported a quarterly loss of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.04.
• Earnings surprise of 50% and surpassed consensus EPS estimates three times in the last four quarters.
• Posted revenues of $8.2 million for March 2024, exceeding estimates by 9.45%.
• Stock has lost 11.6% this year compared to S&P 500's gain of 5.6%.

Future Outlook for KORU Medical Systems Inc.:

• Uncertainty about stock performance, dependent on management's commentary and earnings outlook.
• Estimate revisions trend is mixed, translating into a Zacks Rank #3 (Hold).
• Current consensus EPS estimate for coming quarter is -$0.04 on $7.7 million in revenues.

Inogen Inc. Expectations:

• Inogen, another medical instruments company, yet to report Q1 results.
• Expected to post a quarterly loss of $0.76 per share with revenues of $73.28 million.

Zacks Investment Research Recommendations:

• Zacks expert picks 5 stocks set to double in 2024.
• Previous recommendations have shown significant gains.
• Most stocks in the report are under Wall Street radar, offering potential opportunities.

• Adjusted EPS for Q1 2024 was $(0.02), beating the estimated $(0.04).
• Sales for Q1 2024 were $8.198 million, surpassing the estimated $7.467 million.